101 related articles for article (PubMed ID: 20542847)
1. Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients.
Reliquet V; Allavena C; Morineau-Le Houssine P; Mounoury O; Raffi F
HIV Clin Trials; 2010; 11(2):110-7. PubMed ID: 20542847
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
4. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Gathe J; Andrade-Villanueva J; Santiago S; Horban A; Nelson M; Cahn P; Bogner J; Spencer D; Podzamczer D; Yong CL; Nguyen T; Zhang W; Drulak M; Quinson AM
Antivir Ther; 2011; 16(5):759-69. PubMed ID: 21817198
[TBL] [Abstract][Full Text] [Related]
6. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.
van den Berg-Wolf M; Hullsiek KH; Peng G; Kozal MJ; Novak RM; Chen L; Crane LR; Macarthur RD;
HIV Clin Trials; 2008; 9(5):324-36. PubMed ID: 18977721
[TBL] [Abstract][Full Text] [Related]
7. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
8. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
[TBL] [Abstract][Full Text] [Related]
9. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
de Beaudrap P; Etard JF; Guèye FN; Guèye M; Landman R; Girard PM; Sow PS; Ndoye I; Delaporte E;
AIDS Res Hum Retroviruses; 2008 Jun; 24(6):753-60. PubMed ID: 18507521
[TBL] [Abstract][Full Text] [Related]
11. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
Keiser P; Nassar N; White C; Koen G; Moreno S
HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
Zhou H; Zheng Y; He Y; Gong G; Chen Z; Liu M; Yin W; Liu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 34(8):731-7. PubMed ID: 19734579
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
14. Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
Sanjeeva GN; Sukanya V; Pavithra HB; Dodderi SK; Rewari BB; Govindaraj M; Shivananda S; Premalatha R
AIDS Care; 2015; 27(5):655-9. PubMed ID: 25517472
[TBL] [Abstract][Full Text] [Related]
15. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Smith DE; Chan DJ; Maruszak H; Jeganathan S
Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757
[TBL] [Abstract][Full Text] [Related]
17. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
[TBL] [Abstract][Full Text] [Related]
18. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
19. Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study.
Lee YC; Lin SW; Chen MY; Chang SY; Kuo CH; Sheng WH; Hsieh SM; Sun HY; Chang HY; Wu MR; Liu WC; Wu PY; Yang SP; Zhang JY; Su YC; Luo YZ; Hung CC; Chang SC
PLoS One; 2015; 10(10):e0140574. PubMed ID: 26465325
[TBL] [Abstract][Full Text] [Related]
20. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
